How We WorkOrder NowSupport Privacy

Allergan (NYSE:AGN) to Acquire SkinMedica for $350M: Stocks In The News – CYBX, AGN, BSX, DVAX

on 19/11/2012

NEW YORK, NY, Nov 19, 2012 — (Net PR News) – AnotherWinningTrade.comoffers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.comprovides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

Today’s Stocks in focus are:NASDAQ:CYBX, NYSE:AGN, NYSE:BSX, NASDAQ:DVAX,

Cyberonics, Inc. (NASDAQ:CYBX) announced on Friday it fiscal Q2 earnings surged 50 percent, thanks in part to a warrant-liability increase, as the medical-device maker’s sales beat consensus anticipates.

The firm also increased its full-year earnings to $1.56 and $1.62 per share from its June estimate of $1.49 to $1.59 per share and increased its sales outlook by $5M, now anticipating $246 million to $249 million.

Analysts polled by Thomson Reuters had estimated earnings of 39 cents per share on revenue of $60M.

For the quarter ended Oct. 26, Cyberonics announced a profit of $13.6M, or 48 cents per share, increased from $9.03M, or 32 cents, the year before. Exclusive of items like a gain on warrant liability, adjusted per-share earnings were 44 cents in the most-current quarter. Sales surged 17% to $63 million.

Cyberonics, Inc. (NASDAQ:CYBX) reported the gain of +12.53% and closed at $52.44 with the total traded volume of 1.01 million shares. Its price to sales ratio ended at 6.40 and its price to cash per share was $14.14. Its market capitalization is $1.45 billion. Cyberonics, Inc.’s stock (NASDAQ:CYBX) owned by Financial Institutions was 97.82% while by insiders was 2.95%.

Is CYBX a solid investment at these levels? Find out EXACTLY where CYBXis headed with this TREND ANALYSIS REPORT

Allergan, Inc. (NYSE:AGN) announced on Friday that it decided to purchase SkinMedica Inc.’s topical-aesthetics skin-care business for $350 million to raise its presence in the skin-care market.

The agreement comprises an additional $25M in payments, dependent on SkinMedica products reaching certain sales goals.

Allergan’s CEO, DavidE.I.Pyott, stated that the SkinMedica purchase should complement its existing businesses, including Botox, the facial-wrinkle treatment Juvederm and Latisse, a treatment to produce eyelashes.

It will facilitate them to take a leadership position in the rising ‘physician-dispensed’ topical-aesthetics skin-care category, he added.

Allergan, Inc. (NYSE:AGN) has the market capitalization of $26.66 billion, enterprise value of $25.28 billion. The company has the price over sales value of $4.64whereas its price over book value was $4.74 for the most recent quarter. Allergan, Inc. (NYSE:AGN) has the total cash of $2.93 billion as compared to total debt of $1.56 billion for the most recent quarter with the current ratio of 4.30 for the most recent quarter.

The stock has a 52-week high price of $97.09 and its 52-week low was recorded at $78.42, 50-Day moving average was $91.73 and 200-Day moving average was $13.49.

Is AGN going to gain as many investors expect it to or will shares return to their 52week Highs? Find out what is going on with AGNwith a FREE TREND REPORT

 

Boston Scientific Corporation (NYSE:BSX) reported the increase of +0.59% to close at $5.14 with the overall traded volume of 10.52 million shares. Its market capitalization was $7.06 billion. Its debt to equity ratio was 1.75. Its beta value stands at 1.03 times and return on equity was -43.84%.

Boston Scientific Corporation (NYSE:BSX) has the total of 1.37 billion outstanding shares as compared to 1.36 million shares that were floated in the market.

Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide.

Can BSX Extend this Massive Gain? Find Out in This Trend Analysis Report

Dynavax Technologies Corporation (NASDAQ:DVAX) moved down-47.30% to close at $2.44. Its total traded volume during the last trading session was 35.41 million shares. Dynavax Technologies Corporation (NASDAQ:DVAX)’s 5 years revenue rate remained 34.85%. The total market capitalization is $436.05 billion. It declined -64.55% return on Equity, -56.46% return on Investment and -46.77% return on Assets.

How Should Investors Trade DVAX Now? Don’t Trade DVAX until you Read this Trend Analysis Report

Disclaimer:

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

 

 

Source: anotherwinningtrade Posted Mon, November 19, 2012 13:33 - Permalink